Table 3.
Univariate and multivariate analysis for predictors of survival in neuroblastoma
| Prognostic factors | Univariate (χ2, log‐rank) | P‐value | Multivariate (relative risk & 95% CI) | P‐value |
|---|---|---|---|---|
| Patients found by mass‐screening or clinically (n = 217) | ||||
| Serum NM23‐H1(< 250/> 250 ng/mL) | 11.211 | 0.0008 | 1.7294 (0.7997–3.7398) | 0.1639 |
| Age (< 12/≥ 12 months) | 32.353 | < 0.00001 | 3.8979 (1.3818–10.996) | 0.0101 |
| Stage (1, 2, 4s/3, 4) | 33.142 | < 0.00001 | 8.2514 (1.8173–37.466) | 0.0063 |
| NMYC amplification (–/+) | 43.997 | < 0.00001 | 2.3253 (1.0541–5.1297) | 0.0366 |
| Patients found clinically (n = 86) | ||||
| Serum NM23‐H1(< 250/> 250 ng/mL) | 4.493 | 0.0340 | 1.6143 (0.7386–3.5282) | 0.2299 |
| Age (< 12/≥ 12 months) | 5.825 | 0.0158 | 1.4742 (0.4877–4.4563) | 0.4916 |
| Stage (1, 2, 4s/3, 4) | 6.994 | 0.0082 | 3.5721 (0.7158–17.826) | 0.1206 |
| NMYC amplification (–/+) | 7.749 | 0.0054 | 1.9682 (0.9016–4.2967) | 0.0892 |
CI, confidence interval.